Stefan Cross insider trades: HedgePath Pharmaceuticals (HPPI) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stefan reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2017 | HPPI | ↑ Buy | 600,000 | $162660.00 | $97.60B | Direct | Feb 12, 2018 (55d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Stefan Cross's insider trades
Stefan Cross is a director at HedgePath Pharmaceuticals (HPPI). Since Dec 19, 2017, Stefan has reported 1 open-market purchase worth $97.60B and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (1 filing), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HPPI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.